The NIHR have recently published an article on the STAMPEDE trial which is helping to improve the prognosis and quality of life of those diagnosed with prostate cancer.
This is a research study that’s supported by the NIHR, and has been up and running since 2005, with more than 10,000 men having taken part. 125 UK sites are conducting the research, with local NHS Trusts amongst those 125.
The trial is multi-arm, so compares different treatments amongst the participant group – it is also ‘randomised’, so participants are allocated their treatment at random, reducing any bias in allocation.
The results to date from the trial have also influenced the NHS treatment for men with high risk, locally advanced metastatic prostate cancer. More STAMPEDE related news can be found on their website.
You can read the article here, which contains a testimony from a trial participant whose condition and quality of life have been vastly improved.
Prostate Cancer Research Centre – your chance to influence their next call
New report highlights how NIHR support for clinical research benefits the UK economy and NHS
Cancer and Nutrition NIHR Infrastructure Collaboration
RKEDF – Overview of NIHR, CRNs and NIHR portfolio
BU academics publish in Nepal national newspaper
New BU Physiology paper
Gender and street names
Help Shape the Future of Research at BU: Postgraduate Research Experience Survey 2026 Now Open
3C Event: Research Culture, Community & Cherry Blossom – Tuesday 14 April
REMINDER: 3MT® Competition – Deadline 9am Monday 20 April
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease